From January 1, 2023 to March 31, 2023, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 988,501 shares, representing 0.13% for CNY 18.93 million under the buyback announced on September 1, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.97 CNY | -2.31% | -6.14% | +2.68% |
05-09 | Pacific Shuanglin Bio-pharmacy Subsidiary Gets Plasmapheresis License | MT |
04-26 | Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.68% | 2.83B | |
-0.07% | 91.42B | |
+2.76% | 41.08B | |
-9.06% | 34.26B | |
+55.32% | 25.27B | |
-16.61% | 15.27B | |
-9.14% | 12.81B | |
-12.11% | 11.6B | |
-43.61% | 11.42B | |
+7.79% | 9.16B |
- Stock Market
- Equities
- 000403 Stock
- News Pacific Shuanglin Bio-pharmacy Co., LTD
- Tranche Update on Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback Plan announced on September 1, 2022.